Julia E Maxson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4249547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. Current Oncology, 2022, 29, 805-815.	2.2	3
2	PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia, 2022, , .	7.2	7
3	A new role for hematoxylin: targeting CALR. Blood, 2021, 137, 1848-1849.	1.4	2
4	Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia, 2021, 35, 3594-3599.	7.2	15
5	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, 2021, 12, 5337.	12.8	14
6	Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia. Blood, 2020, 135, 1603-1606.	1.4	15
7	Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13670-13679.	7.1	24
8	Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. Nature Communications, 2019, 10, 5455.	12.8	22
9	Single Cell RNA Sequencing Identifies a Crucial Role for ASXL1 in Neutrophil Development. Blood, 2019, 134, 212-212.	1.4	1
10	SETBP1 Mutations Accelerate NRAS-Mutant Leukemia. Blood, 2019, 134, 1254-1254.	1.4	0
11	Gain-of-function mutations in granulocyte colony–stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. Journal of Biological Chemistry, 2018, 293, 7387-7396.	3.4	22
12	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer Research, 2018, 78, 6762-6770.	0.9	17
13	Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. Science Signaling, 2018, 11, .	3.6	16
14	Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia. Blood, 2018, 132, 3067-3067.	1.4	0
15	Genomics of chronic neutrophilic leukemia. Blood, 2017, 129, 715-722.	1.4	74
16	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood, 2016, 127, 3094-3098.	1.4	49
17	Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research, 2016, 76, 127-138.	0.9	31
18	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618L Clinical Cancer Research. 2016, 22, 757-764.	7.0	40

Julia E Maxson

#	Article	IF	CITATIONS
19	Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research, 2015, 75, 2146-2150.	0.9	20
20	Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization. Journal of Biological Chemistry, 2014, 289, 5820-5827.	3.4	51
21	Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports, 2014, 3, 67-69.	0.4	62
22	Oncogenic <i>CSF3R</i> Mutations in Chronic Neutrophilic Leukemia and Atypical CML. New England Journal of Medicine, 2013, 368, 1781-1790.	27.0	499
23	The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood, 2013, 122, 3628-3631.	1.4	95
24	Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	2